Not applicableStudy completedNCT05129241
What this trial is testing
Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector
Who this might be right for
Primary Hypercholesterolaemia and Mixed DyslipidaemiaAtherosclerotic Cardiovascular Disease
Sanofi 163